What changed at the factory and which registered models are affected?
This guide is written for Singapore medical-device registrants, distributor quality and receiving teams procuring an already SMDR-listed sterile single-use device, and overseas product owners or OEM contract manufacturers preparing the transfer dossier. It addresses one operational handoff: deciding which regulatory evidence to demand before filing a post-registration site change in Singapore and which production lots may enter commercial supply once the transfer begins.
A factory change notice can cover several changes at once. An assembly move, a different sterilizer and a revised pouch may appear in the same supplier email. Classify each actual change and identify the affected SMDR listings in Annex 2. Use a model-level crosswalk to carry that scope into SHARE, Singapore’s Health Product Access and Regulatory E-System.138
Before classifying the site move, confirm three baseline facts on the actual SMDR listing and in the SHARE portal:
- Risk class and listing scope: GN-21 Change Notification applies only to Class B, Class C and Class D devices registered on the SMDR. Under section 2.1, Class A devices are exempted from product registration and Change Notification and are maintained instead in the Class A Medical Device Database under GN-22, while dealer licensing and post-market duties still apply.1
- Exact site action and activity: Separate whether the supplier is adding an extra site, deleting an unused site, or replacing an existing manufacturing or sterilization site—because replacement with overlapping supply triggers an extra phase-out filing duty under section 4.2.1
- Active Change Notifications: Check every listing before filing. Annex 2 asks whether an application is ongoing and requests its job reference. If any listing already has two active applications, HSA rejects the entire incoming filing without refunding any fees paid.8 HSA also limits concurrent device-form amendments to one of those applications. On the SHARE listing, check Related Applications and confirm whether the pending filing edits the device form before submitting a site change.9
| What actually changed | GN-21 type | Class B category | Class C & D category | Implementation gate and boundary |
|---|---|---|---|---|
| Addition, deletion or move of a manufacturing or sterilization site with unchanged applicable processes, registered specifications and sterile primary packaging | 1A | Notification | Notification | Implement upon SHARE acknowledgement email; replacement with concurrent supply requires old-site phase-out timeline, valid old-site QMS and HSA review.1 |
| Manufacturing process changed to Additive Manufacturing (3D-printing) or refurbishing | 1B | Notification | Technical | Class C/D requires prior HSA approval; check Flowchart 1.1 before assuming a pure site move.1 |
| Manufacturing site and/or process change that alters registered device specifications | 1C | Notification | Technical | Class C/D requires prior HSA approval, new process summary, design V&V and risk analysis where applicable.1 |
| Change in sterilization method or related process (e.g., EO to gamma, cycle parameters or parametric release) | 1D | Notification | Technical | Class C/D requires prior HSA approval, sterilization validation (incl. EO residuals if applicable), ongoing validation and post-sterilization functional V&V.1 |
| Change in sterile primary packaging (e.g., foil laminate to Tyvek pouch, or tray removal) | 2Ai | Notification | Technical | Evaluated from Flowchart 1.2 / Flowchart 2.2; Class C/D requires prior HSA approval, V&V, risk analysis and clinical evidence if applicable.1 |
| Material supplier swap (non-medicinal, non-biological) with no change to registered specifications | No CN (§2.3) | No CN | No CN | Limited to eligible material suppliers. Check the material pathways separately for biological materials and any other changes to the device; assess a move of finished-device manufacturing or sterilization facilities under the site flowcharts.1 |
| Update of QMS certificate validity date only | 1E | Notification | Notification | Cannot be used to disguise a physical facility relocation or a new site address.1 |
| Change in intended purpose, risk classification, ancillary medicinal substance, or proprietary names/models outside GN-12 grouping criteria | Excluded (§2) | New registration | New registration | Does not qualify for Change Notification; requires a new premarket product registration.1 |
Source: HSA GN-21 Revision 7 (August 2026), §§2, 2.1–2.3, Flowcharts 1.1, 1.2, 3 and Annexes 1 & 3.
Annex 1 directs registrants to ask HSA’s Medical Devices Cluster for advice before changing the manufacturing or sterilization site of a device that incorporates an ancillary medicinal product. The material-supplier exemption in section 2.3 covers eligible changes that leave registered specifications unchanged. Check the facility’s actual role before applying it.1
When does a site move qualify as Type 1A?
Start at the top of Flowchart 1.1 for manufacturing and Flowchart 1.2 for sterilization. Type 1A sits below the questions that identify higher-impact changes. Even if those earlier branches do not apply, a pure site transfer still has to satisfy the unchanged-process condition in the applicable flowchart.1
- Manufacturing: Check whether the process change affects an ancillary medicinal substance, introduces additive manufacturing or refurbishing (1B), changes registered device specifications (1C) or affects sterilization. If it affects sterilization, follow Flowchart 1.2 as well. For a manufacturing site move, the 1A branch specifies an unchanged manufacturing process.1
- Flowchart 1.2 upper gates: Does the sterilization transfer change the sterilization method or related parameters, such as chamber loading, cycle parameters, switching from EO to gamma, or moving from batch release to parametric release (1D)? Does it change the sterile primary packaging, such as removing a tray or switching from foil laminate to a Tyvek pouch (2Ai)? Only when both answers are No does the sterilization-facility move qualify as Type 1A.1
- Other effects: Work through the main flowchart for other changes, including materials and labeling. A change to a body-contacting material may follow 3Bi or 3Bii depending on what changes. Assess shelf-life and stability changes under the specification branch (2B) and evaluate any resulting label changes separately.1
Combined changes, misclassification and safety actions
For changes grouped in one eligible application, HSA assesses the filing and applies fees and turnaround based on the most stringent category. For example, if a Class C site move also changes its sterile primary packaging (2Ai), the combined filing requires Technical review. GN-21 lists target Technical turnaround of 75 working days for Class C and 90 working days for Class D, excluding time awaiting applicant responses to clarification or information requests. These targets are planning inputs.1
HSA can reject a filing after finding that a change was incorrectly submitted as a Notification. Further supply is then prohibited until HSA approves the change under the correct category. HSA does not refund application fees paid on SHARE.1
Classify changes linked to an open reportable adverse event (AE) or ongoing field safety corrective action (FSCA) using the same flowcharts. Section 2.2 adds a separate implementation requirement. The change needs prior HSA approval regardless of category unless HSA advises otherwise in writing. The six-month Notification bundling provision does not apply. Where relevant, record the FSCA reference in Annex 2 and check whether HSA needs additional safety or corrective-action evidence.18
If the transfer also includes an administrative model addition under 6Aii or 6Aiii, confirm the release gate with HSA before implementation. The service page permits implementation after acknowledgement for those two types, while GN-21 Revision 7 calls for prior approval. This discrepancy does not affect ordinary, standalone Type 1A Notifications.12
What must the product owner give the Singapore registrant?
Singapore separates the commercial factory from the local regulatory holder. The Singapore Registrant—the local corporate entity holding the SMDR listing and Corppass access to SHARE—submits the Change Notification and answers HSA input requests.13 The overseas Product Owner (and any contract manufacturer or sterilizer) controls the technical evidence, QMS certificates and official letterhead declarations.1 Because SHARE permits no unilateral amendments once an application is submitted unless HSA advises otherwise, the product owner and registrant must reconcile the full package before submission.1
Understanding the portal mechanics helps explain why incomplete handoffs stall shipments. HSA’s SHARE Change Notification Quick Guide separates updating or adding manufacturing and sterilization facility details from assigning that updated site to each individual device model on the listing.3 If a supplier sends an ISO 13485 certificate for a new plant without confirming which exact catalogue codes or sizes on the SMDR listing are transferring, the registrant cannot verify model-level assignment in SHARE—and an incomplete Annex 2 model scope can leave specific SKUs unmapped.
Under section 4 Note 3, identical Type 1A manufacturing or sterilization site changes affecting SMDR listings of different risk classes (for example, a Class B suture and a Class C surgical kit produced at the same facility) may be bundled into one Change Notification application on SHARE.1 Check the grouping rule in section 4 before combining other changes or filings that span more than one listing.1 For supplier qualification before a transfer, see our guide to qualifying a sterile-device contract manufacturer.
| Evidence item | Type 1A (site-only) | Escalated (1C / 1D / 2Ai) | Required source and scope | Recommended buyer/registrant redline check |
|---|---|---|---|---|
| Annex 2 Summary Table of Change Notification | Mandatory | Mandatory | Record type and category, SMDR listing number, current and proposed site details, reason and reference-agency status. Declare related safety actions and any ongoing notifications, including job references.18 | Confirm every affected SMDR listing and SKU code is listed and no listing already carries two active CNs. |
| Proof of QMS for the new/affected site | Mandatory | Mandatory (1D); If applicable (1C) | Annex 1 lists ISO 13485 and MDSAP certificates among its examples of QMS evidence. Check whether the evidence covers the affected facility and activity.1 | Match exact legal entity, street address and scope (manufacture vs. EO sterilization) against the proposed site; if replacing an old site with concurrent supply, also collect valid old-site QMS.1 |
| Device labeling | Mandatory | Mandatory (1D, 2Ai); If applicable (1C) | Provide final device labeling and identify any changes on the marked-up copy.1 | Check whether manufacturer/site address, UDI, storage conditions or language changed; verify no unfiled Flowchart 5 labelling edits slipped in. |
| Product-owner declaration letter | Mandatory | Not listed for 1C/1D/2Ai | A declaration on product-owner letterhead confirming that the device is unchanged, including its intended use, technical specifications and applicable sterilization process.1 | Ensure the letter names the exact SMDR-listed device family/models and comes from the registered Product Owner, not only a sub-tier OEM. |
| Sterilization validation & ongoing validation | If applicable | Mandatory (1D) | Sterilization validation report (including EO residuals report if applicable) and ongoing validation evidence.1 | Ask how the validation covers the moved models, packaging and load configuration. Annex 1 gives a post-sterilization functional test report as an example of design verification and validation for 1D.1 |
| New manufacturing process summary, Design V&V & Risk Analysis | Not required for pure 1A | Mandatory (1C process summary and V&V; 1D V&V; 2Ai V&V and risk analysis) | Process summary (1B/1C), design V&V (1B/1C/1D/2Ai), risk analysis (1B/1C if applicable; 2Ai mandatory) and clinical evidence if applicable (2Ai).1 | Request a before/after process and primary-packaging redline from the supplier upfront to prove none of these triggers occurred. |
Source: HSA GN-21 Revision 7 Annex 1 (pp. 38–40) and Annex 2 (pp. 53–56); SHARE Quick Guide v1.1. Buyer redline column reflects editorial due-diligence practice, not extra HSA statutory mandates.
When can the distributor release new-site lots?
For a Singapore distributor or hospital buyer, the highest-risk error in a factory transfer is treating three separate events—the supplier’s change notice, the registrant’s SHARE submission, and HSA’s regulatory response—as the same green light. GN-21 Revision 7 separates them cleanly:1
- Ordinary Type 1A Notification: May be implemented immediately upon receipt of the acknowledgement email from HSA after submission via SHARE—assuming no Review/Technical/Administrative category applies, no AE/FSCA trigger exists, and no replacement-site concurrent supply is sought.12
- Prior approval: Technical changes (including 1C, 1D and 2Ai for Classes C and D) and Review changes require HSA approval. Apply the separate safety-action provision under section 2.2 and confirm any mixed filing that includes an administrative change.12
- Replacement-site concurrent supply under Type 1A (§4.2): When a Type 1A filing replaces an existing manufacturing or sterilization site with a new site and the company needs to supply devices concurrently from both the old and new sites, GN-21 section 4.2 imposes an additional condition: the applicant must inform HSA of the proposed timeline for phasing out manufacturing activity at the old site, supported by a valid QMS certificate for the old site. HSA may allow concurrent supply for a stipulated timeline upon review of the information and supporting documents provided.1
Where concurrent supply is permitted, both versions must meet the applicable Essential Requirements for Safety and Performance. Use lot, serial or other production identifiers and the manufacturing date as appropriate to distinguish the original and changed devices. Retain the inventory records for HSA inspection. For a site replacement, confirm the overlap that HSA allows and record its conditions before accepting overlapping shipments.1
GN-06 requires Singapore registrants, manufacturers, importers and wholesalers to maintain distribution records. The records should allow the business to identify who made each batch and where it was sent. Useful fields include the initial consignee, shipping date, device and quantity, and the lot, batch or serial number.4 If a Singapore dealer’s own declared particulars change, check the separate licence amendment in SHARE. An overseas factory move alone does not establish that the local dealer’s particulars have changed.5 For the underlying roles, see our guide to Singapore device registration and registrant roles.
Copy-ready manufacturing-site change and lot-release record
Rather than scattering a factory transfer across supplier emails, PDF certificates and ERP receiving notes, capture the product owner’s filing evidence and the distributor’s lot-disposition decision in one controlled workpaper. The template below combines official GN-21 / SHARE / GN-06 anchors (marked in the basis column) with recommended buyer and registrant reconciliation fields.
| Record field | What to record | Primary owner | Documentary anchor / editorial basis |
|---|---|---|---|
| 1. SMDR listing & SKU scope | Record the SMDR listing, risk class, affected model codes and ongoing application references. Check the total open applications and whether a pending application already edits the device form. | Singapore Registrant | Annex 2, HSA’s concurrent filing FAQ and the SHARE model link.893 |
| 2. Before/after site & activity | Present vs. Proposed legal entity name, street address, role (manufacturing vs. sterilization) and action (add / delete / replace) | Product Owner / OEM | GN-21 R7 Annex 2 Present/Proposed columns (pp. 54–55)1 |
| 3. Flowchart & escalation screen | Yes/No results for 1B, 1C (specs), 1D (sterilization method/process), 2Ai (sterile primary pack), 3A/3Bi/3Bii (materials), Flowchart 5 (labelling), and §2.2 (open AE/FSCA) | Product Owner & Registrant | GN-21 R7 Main Flowchart, Flowcharts 1.1–1.2, §§2.2, 41 |
| 4. Applicable CN category | List the applicable change codes and filing category. Check whether the changes qualify to be filed together and whether a safety action changes the implementation requirement. | Singapore Registrant | GN-21 R7 §2, §4 Note 3 (p. 31), Annex 31 |
| 5. Annex 1 / Annex 2 pack | Annex 2 plus the applicable Annex 1 evidence. For a pure 1A transfer, record site QMS evidence, final and marked-up labeling, product-owner declaration and applicable sterilization validation. | Product Owner furnishes; Registrant checks | GN-21 R7 Annex 1 (pp. 38–39) & Annex 21 |
| 6. SHARE filing & HSA response | SHARE application reference, submission date, model-to-site assignment verified, and exact HSA response (acknowledgement email vs. approval letter vs. input request) | Singapore Registrant | GN-21 R7 §§2, 4.1–4.2; SHARE Quick Guide §§8–10123 |
| 7. Old-site phase-out window | If replacing a site with concurrent supply: submitted old-site phase-out timeline, valid old-site QMS expiry date, and HSA’s stipulated concurrent-supply end date | Registrant & Product Owner | GN-21 R7 §4.2 replacement-site clause (p. 35)1 |
| 8. Batch provenance & release | Match the shipment and lot identifier to the manufacturing date and site records supplied by the manufacturer or sterilizer. Record the applicable HSA response and the receiving team’s hold or release decision. | Distributor QA / Importer | GN-21 R7 §4.2 differentiation rule (p. 34); GN-06 R3 §§2–4 traceability; recommended buyer control14 |
Source: Regulatory anchors from HSA GN-21 R7, SHARE Quick Guide v1.1 and GN-06 R3; owner assignments and commercial disposition fields are VEMERIX editorial recommendations.
Three hypothetical sterile-device site-transfer cases
These examples use a fictional Class C sterile surgical kit, model SK-30. Each starts from an existing SMDR listing and tests a different release decision.
Case 1. Assembly moves with the process unchanged
The product owner moves final assembly of the SK-30 kit from Factory A to Factory B. It documents that the assembly process, materials, specifications, primary packaging and outsourced sterilization process remain the same. No related AE or FSCA is open and the two factories will supply in sequence. The registrant records the reference for the one other active application and confirms it does not amend the device form or depend on this transfer.189
The product owner supplies Factory B’s QMS evidence, final labeling, any marked changes, the no-change declaration and applicable sterilization validation evidence. The registrant files Annex 2 and links Factory B to the affected model in SHARE. The receiving team logs HSA’s acknowledgement and matches the first new lot to Factory B before release.138
Case 2. The transfer also changes the pouch or sterilization process
During the move to Factory B, the supplier also changes the sterile primary pouch. The pouch change maps to 2Ai. If the supplier instead changes the sterilization method or related process, that change maps to 1D. Record the actual site and process changes together so the filing reflects the final configuration.1
Both branches call for Technical review for this Class C device. The pouch change calls for design verification and validation and risk analysis, with clinical evidence where applicable. A sterilization process change calls for validation and evidence of ongoing validation. EO residuals are applicable where required, and Annex 1 gives post-sterilization functional testing as an example of the design evidence. The buyer holds the changed lots pending HSA approval and reconciling the affected models and lots against that decision.1
Case 3: Site replacement requiring overlapping supply from both old and new sites
Factory B qualifies cleanly under Type 1A, but Factory A is being replaced rather than retained permanently. The Singapore distributor needs two more quarters of inventory from Factory A while Factory B ramps up. Under GN-21 section 4.2’s replacement-site paragraph, the company cannot rely on an ordinary Notification receipt alone to run both supply streams.1
The registrant gives HSA the proposed phase-out timeline for old-site activity and a valid Factory A QMS certificate. The receiving team records the period and any conditions HSA allows, then traces each shipment to its manufacturing site and date using lot identifiers and manufacturer or sterilizer records. For an AE- or FSCA-related change, follow HSA’s written advice on further supply of affected and corrected stock.14
| Hypothetical scenario | GN-21 type & category | Governing HSA gate before supply | Key lot & QMS check for the buyer |
|---|---|---|---|
| Case 1: Factory A → B assembly move; identical process, specs, primary pack and EO cycle | 1A (Notification) | HSA’s acknowledgement email after SHARE submission1 | Confirm the model-to-site link in SHARE and match the first changed lot to Factory B. |
| Case 2: Factory A → B move + Tyvek pouch switch (2Ai) or sterilization process/method shift (1D) | 2Ai for the pouch or 1D for the sterilization change. A combined Class C filing is Technical. | Prior HSA approval (75-working-day target, excluding stop-clock time)1 | Hold changed lots while the filing is pending. |
| Case 3: Factory A replaced by B, with overlapping shipments needed from both | 1A (Replacement-site §4.2) | Confirm HSA’s decision on overlap, supported by the phase-out plan and valid old-site QMS certificate.1 | Match the shipments from each site to the dates and conditions HSA allows. |
Source: Illustrative scenarios built on HSA GN-21 Revision 7 §§2, 2.2, 4.1–4.2, Flowcharts 1.1–1.2, Table 2 and Annex 1.
Pre-shipment checklist for buyers and Singapore registrants
- Confirm the listing and filing capacity: Verify the exact SMDR listing, risk class and model codes. Check whether the listing already has two active applications or a pending application that edits the SHARE device form.9
- Classify the actual changes: Check the manufacturing and sterilization branches, then assess related specification, packaging, materials and labeling changes.1
- Check for a linked safety action: When the proposed change arises from an open reportable AE or ongoing FSCA, confirm HSA’s prior approval or written advice permitting otherwise.1
- Check the submission pack: Use the current Annex 2 template and assemble the Annex 1 evidence for each applicable change type.18
- Verify SHARE model assignment: Confirm the registrant both updated the facility entry and assigned the site to the individual device models in SHARE before final submission.3
- Match the response to the filing: Log HSA’s acknowledgement for a standalone Type 1A Notification or the applicable approval for a change that requires prior review.12
- Confirm the replacement-site overlap: Check the proposed phase-out timeline, valid old-site QMS certificate and overlap HSA allows.1
- Match lot provenance and local dealer particulars: At receiving, verify batch/lot/serial numbers, manufacturing dates and producing site on shipping records against GN-06 distribution traceability, and confirm separately whether the Singapore dealer’s own licence particulars changed.145
Requesting a VEMERIX technical pack
VEMERIX is the international brand of Weihai Medison Medical Equipment Co., Ltd., positioned as a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery and perioperative care. Within the VEMERIX surgical portfolio, products such as the Disposable Sterile Circumcision Device are supplied as single-use, factory ethylene-oxide-sterilized medical devices (registered in China as a Class II device under Lu Mech Reg. 20222021157).7 Confirm the Singapore risk class and listing for the exact model with the local registrant.
For international distributors and OEM/ODM partners evaluating VEMERIX sterile disposables or planning a controlled site, packaging or sterilization qualification, the practical starting point is to align quality records early. Review our quality and regulatory capabilities and submit a technical-pack enquiry specifying your target market, exact product or model, whether a proposed site change adds or replaces a facility, the affected manufacturing or sterilization activity, and the planned first changed lot.
Frequently asked questions
Does using the same contract manufacturer at another address settle the change type?
Start with what changes at the address. Type 1A covers a site-only move under the applicable unchanged-process condition. If the transfer affects a registered specification, sterilization or sterile primary packaging, assess 1C, 1D or 2Ai as applicable. A manufacturing-process difference that does not map cleanly to those branches warrants confirmation with HSA before filing.1
What if the sterilizer moves and the sterilization process changes too?
Assess the sterilization change under 1D. For Classes C and D, this is a Technical Change requiring prior HSA approval. Annex 1 calls for sterilization and ongoing validation evidence and design verification and validation. Include EO residuals where applicable.1
Does an updated QMS certificate alone allow supply from the new site?
A certificate validity update alone is Type 1E. For a physical site transfer, use the applicable Annex 1 evidence, complete Annex 2 and check the affected models in SHARE. For a site-only 1A change, Annex 1 also calls for the product owner’s no-change declaration.138
Can distributors continue to sell lots from both the replaced and replacement site?
First confirm that HSA allows the overlap and identify any conditions. For a Type 1A site replacement, section 4.2 calls for the old site’s proposed phase-out timeline and a valid old-site QMS certificate. Keep the two streams traceable by lot or other production identifiers. If a safety action drives the change, check HSA’s written instructions for affected and corrected stock.1
Do Singapore Class A devices use the same Change Notification route?
No. Under GN-21 section 2.1, Change Notification applications should not be submitted for Class A medical devices.1 Class A devices are maintained in the Class A Medical Device Database under GN-22, while dealer’s licensing and post-market regulatory obligations (including distribution records under GN-06) remain applicable.14
Source scope and when to recheck
The source check on 20 November 2026 covered HSA’s current GN-21 Revision 7, its standalone Annex 2 template, the concurrent-filing FAQ, the SHARE application guide and the distribution and dealer-licence guidance.1345689 Recheck the linked guidance before a new filing, especially the implementation rules, site-to-model assignment and any case-specific conditions on overlap.
